Skip to main content

Advertisement

SpringerLink
Log in

Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Not all patients respond well to cancer chemotherapy. One of the most important factors contributing to treatment response (efficacy and toxicity) is genetic determinant. The current systematic review aims to provide current status of the information on the genetic contribution of genes encoding drug transport proteins and drug metabolizing enzyme, cytochrome P450 (CYP), and relationship with clinical outcomes of cancer chemotherapy.

Methods

The literature search was performed through PubMed and ScienceDirect databases. One hundred and four research articles that fulfilled the inclusion criteria and had none of the exclusion criteria were included in the analysis.

Results

Various studies reported conflicting results for the polymorphisms of the major genes and association with treatment outcomes in patients with various types of cancer. Nevertheless, among the investigated gene polymorphisms, it appears that the 1236C>T, 3435C>T and 2677 G>T/A SNPs of the drug transporter gene ABCB1 were the most promising determinants of clinical outcomes. Although both 1236C>T and 3435C>T polymorphism are synonymous SNPs, several studies have demonstrated that not all synonymous SNPs are silent. Therefore, using the haplotype (1236C>T, 2677G>T, and 3435C>T) analysis rather than a single SNP may be a more useful approach for phenotype prediction. Some of the patients with variants of CYP genes were associated with unsatisfactory treatment response (efficacy and toxicity), suggesting that these variants may be associated with either reduction or absence of CYP enzyme activity.

Conclusions

The controversial results may be due to several factors including difference in populations studied, sample size, tumor sites and stages, chemotherapeutic drug regimens, and evaluation parameters for efficacy and/or toxicity. Before the information can be successfully applied to individualized cancer chemotherapy, further studies should be focused on these promising genetic markers and their association with clinical outcomes using standardized protocols.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Obata H, Yahata T, Quan J, Sekine M, Tanaka K (2006) Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer. Anticancer Res 26(3b):2227–2232

    CAS  PubMed  Google Scholar 

  2. Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, Williams RT, Flemming C, Lambrechts D, Despierre E, Lambrechts S, Vergote I, Karlan B, Lester J, Orsulic S, Walsh C, Fasching P, Beckmann MW, Ekici AB, Hein A, Matsuo K, Hosono S, Nakanishi T, Yatabe Y, Pejovic T, Bean Y, Heitz F, Harter P, du Bois A, Schwaab I, Hogdall E, Kjaer SK, Jensen A, Hogdall C, Lundvall L, Engelholm SA, Brown B, Flanagan J, Metcalf MD, Siddiqui N, Sellers T, Fridley B, Cunningham J, Schildkraut J, Iversen E, Weber RP, Berchuck A, Goode E, Bowtell DD, Chenevix-Trench G, deFazio A, Norris MD, MacGregor S, Haber M, Henderson MJ (2014) ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst 106:7. https://doi.org/10.1093/jnci/dju149

    Article  CAS  Google Scholar 

  3. He L, Vasiliou K, Nebert DW (2009) Analysis and update of the human solute carrier (SLC) gene superfamily. Hum Genom 3(2):195–206

    Article  CAS  Google Scholar 

  4. Huang L, Zhang T, Xie C, Liao X, Yu Q, Feng J, Ma H, Dai J, Li M, Chen J, Zang A, Wang Q, Ge S, Qin K, Cai J, Yuan X (2013) SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One 8(10):e77223. https://doi.org/10.1371/journal.pone.0077223

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, Mielke S, Vigano L, Locatelli A, Verweij J, Sparreboom A, McLeod HL (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11(22):8097–8104. https://doi.org/10.1158/1078-0432.ccr-05-1152

    Article  CAS  PubMed  Google Scholar 

  6. Caronia D, Patino-Garcia A, Perez-Martinez A, Pita G, Moreno LT, Zalacain-Diez M, Molina B, Colmenero I, Sierrasesumaga L, Benitez J, Gonzalez-Neira A (2011) Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study. PLoS One 6(10):e26091. https://doi.org/10.1371/journal.pone.0026091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134(1):401–410. https://doi.org/10.1007/s10549-012-2054-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Seredina TA, Goreva OB, Talaban VO, Grishanova AY, Lyakhovich VV (2012) Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med Genet 13:45. https://doi.org/10.1186/1471-2350-13-45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Campa D, Muller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F, Risch A (2012) A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. Int J Cancer 131(12):2920–2928. https://doi.org/10.1002/ijc.27567

    Article  CAS  PubMed  Google Scholar 

  10. Li Z, Xing X, Shan F, Li S, Li Z, Xiao A, Xing Z, Xue K, Li Z, Hu Y, Jia Y, Miao R, Zhang L, Bu Z, Wu A, Ji J (2016) ABCC2-24C>T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients. Oncotarget 7(34):55449–55457. https://doi.org/10.18632/oncotarget.10961

    Article  PubMed  PubMed Central  Google Scholar 

  11. Choi JH, Ahn MJ, Rhim HC, Kim JW, Lee GH, Lee YY, Kim IS (2005) Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer Res Treat 37(5):290–293. https://doi.org/10.4143/crt.2005.37.5.290

    Article  PubMed  PubMed Central  Google Scholar 

  12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 11). Eur J Cancer (Oxford, England: 1990) 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  Google Scholar 

  13. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. https://doi.org/10.1002/cncr.11660

    Article  PubMed  Google Scholar 

  14. Sokal JE, Baccarani M, Russo D, Tura S (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25(1):49–61

    CAS  PubMed  Google Scholar 

  15. Gottesman MM, Pastan I, Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6(5):610–617

    Article  CAS  PubMed  Google Scholar 

  16. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Salagacka A, Mirowski M (2010) ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 25(10):1167–1176. https://doi.org/10.1007/s00384-010-0961-2

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ashariati A (2008) Polymorphism C3435T of the MDR-1 gene predict response to preoperative chemotherapy in locally advanced breast cancer with Her2/neu expression. Acta Med Indones 40(4):187–191

    PubMed  Google Scholar 

  18. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H, Bystrom P, Sorbye H, Wadelius M (2011) Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenom J 11(1):61–71. https://doi.org/10.1038/tpj.2010.10

    Article  CAS  Google Scholar 

  19. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2006) mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy. Clin Cancer Res 12(3 Pt 1):854–859. https://doi.org/10.1158/1078-0432.ccr-05-0950

    Article  CAS  PubMed  Google Scholar 

  20. Ji M, Tang J, Zhao J, Xu B, Qin J, Lu J (2012) Polymorphisms in genes involved in drug detoxification and clinical outcomes of anthracycline-based neoadjuvant chemotherapy in Chinese Han breast cancer patients. Cancer Biol Ther 13(5):264–271. https://doi.org/10.4161/cbt.18920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kim DH, Park JY, Sohn SK, Lee NY, Baek JH, Jeon SB, Kim JG, Suh JS, Do YR, Lee KB (2006) Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia. Int J Cancer 118(9):2195–2201. https://doi.org/10.1002/ijc.21666

    Article  CAS  PubMed  Google Scholar 

  22. Li JZ, Tian ZQ, Jiang SN, Feng T (2014) Effect of variation of ABCB1 and GSTP1 on osteosarcoma survival after chemotherapy. Genet Mol Res 13(2):3186–3192. https://doi.org/10.4238/2014.April.25.3

    Article  CAS  PubMed  Google Scholar 

  23. Wu H, Liu Y, Kang H, Xiao Q, Yao W, Zhao H, Wang E, Wei M (2015) Genetic variations in ABCG2 gene predict breast carcinoma susceptibility and clinical outcomes after treatment with anthracycline-based chemotherapy. Biomed Res Int 2015:279109. https://doi.org/10.1155/2015/279109

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Yan PW, Huang XE, Yan F, Xu L, Jiang Y (2011) Influence of MDR1 gene codon 3435 polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancer. Asian Pac J Cancer Prev 12(9):2291–2294

    PubMed  Google Scholar 

  25. Yang J, Wang ZG, Cai HQ, Li YC, Xu YL (2013) Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Asian Pac J Cancer Prev 14(8):4595–4598

    Article  PubMed  Google Scholar 

  26. Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G (2013) Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 98(2):193–200. https://doi.org/10.3324/haematol.2012.066480

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kim DH, Sriharsha L, Xu W, Kamel-Reid S, Liu X, Siminovitch K, Messner HA, Lipton JH (2009) Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 15(14):4750–4758. https://doi.org/10.1158/1078-0432.ccr-09-0145

    Article  CAS  PubMed  Google Scholar 

  28. Athanasoulia AP, Sievers C, Ising M, Brockhaus AC, Yassouridis A, Stalla GK, Uhr M (2012) Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 167(3):327–335. https://doi.org/10.1530/eje-12-0198

    Article  CAS  PubMed  Google Scholar 

  29. Choi BS, Alberti DB, Schelman WR, Kolesar JM, Thomas JP, Marnocha R, Eickhoff JC, Ivy SP, Wilding G, Holen KD (2010) The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol 66(5):973–980. https://doi.org/10.1007/s00280-010-1250-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Chu YH, Li H, Tan HS, Koh V, Lai J, Phyo WM, Choudhury Y, Kanesvaran R, Chau NM, Toh CK, Ng QS, Tan PH, Chowbay B, Tan MH (2015) Association of ABCB1 and FLT3 polymorphisms with toxicities and survival in asian patients receiving sunitinib for renal cell carcinoma. PLoS One 10(8):e0134102. https://doi.org/10.1371/journal.pone.0134102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C (2015) Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenom J 15(4):372–379. https://doi.org/10.1038/tpj.2014.81

    Article  CAS  Google Scholar 

  32. Han JY, Lim HS, Yoo YK, Shin ES, Park YH, Lee SY, Lee JE, Lee DH, Kim HT, Lee JS (2007) Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 110(1):138–147. https://doi.org/10.1002/cncr.22760

    Article  PubMed  Google Scholar 

  33. Jakobsen Falk I, Fyrberg A, Paul E, Nahi H, Hermanson M, Rosenquist R, Hoglund M, Palmqvist L, Stockelberg D, Wei Y, Green H, Lotfi K (2014) Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype. Br J Haematol 167(5):671–680. https://doi.org/10.1111/bjh.13097

    Article  CAS  PubMed  Google Scholar 

  34. Jamroziak K, Balcerczak E, Smolewski P, Robey RW, Cebula B, Panczyk M, Kowalczyk M, Szmigielska-Kaplon A, Mirowski M, Bates SE, Robak T (2006) MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 58(5):720–728

    CAS  PubMed  Google Scholar 

  35. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G (2008) ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 14(17):5594–5601. https://doi.org/10.1158/1078-0432.ccr-08-0606

    Article  CAS  PubMed  Google Scholar 

  36. Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P (2014) Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 15(12):1565–1574. https://doi.org/10.2217/pgs.14.107

    Article  CAS  PubMed  Google Scholar 

  37. Li Y, Yan PW, Huang XE, Li CG (2011) MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev 12(9):2405–2409

    PubMed  Google Scholar 

  38. Lu Y, Kham SK, Ariffin H, Oei AM, Lin HP, Tan AM, Quah TC, Yeoh AE (2014) Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia. Br J Cancer 110(6):1673–1680. https://doi.org/10.1038/bjc.2014.7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shitara K, Matsuo K, Ito S, Sawaki A, Kawai H, Yokota T, Takahari D, Shibata T, Ura T, Ito H, Hosono S, Kawase T, Watanabe M, Tajima K, Yatabe Y, Tanaka H, Muro K (2010) Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy. Asian Pac J Cancer Prev 11(2):447–452

    PubMed  Google Scholar 

  40. Sissung TM, Baum CE, Deeken J, Price DK, Aragon-Ching J, Steinberg SM, Dahut W, Sparreboom A, Figg WD (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14(14):4543–4549. https://doi.org/10.1158/1078-0432.ccr-07-4230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Argalacsova S, Slanar O, Vitek P, Tesarova P, Bakhouche H, DraZdakova M, Bartosova O, Zima T, PertuZelka L (2015) Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer. Physiol Res 64(Suppl 4):S539–S547

    CAS  PubMed  Google Scholar 

  42. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH (2006) Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res 12(19):5786–5793. https://doi.org/10.1158/1078-0432.ccr-05-2649

    Article  CAS  PubMed  Google Scholar 

  43. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102(6):1003–1009. https://doi.org/10.1038/sj.bjc.6605587

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ceppi F, Langlois-Pelletier C, Gagne V, Rousseau J, Ciolino C, De Lorenzo S, Kevin KM, Cijov D, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Laverdiere C, Krajinovic M (2014) Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics 15(8):1105–1116. https://doi.org/10.2217/pgs.14.68

    Article  CAS  PubMed  Google Scholar 

  45. Kim HJ, Im SA, Keam B, Ham HS, Lee KH, Kim TY, Kim YJ, Oh DY, Kim JH, Han W, Jang IJ, Kim TY, Park IA, Noh DY (2015) ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy. Cancer Sci 106(1):86–93. https://doi.org/10.1111/cas.12560

    Article  CAS  PubMed  Google Scholar 

  46. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811):525–528

    Article  CAS  PubMed  Google Scholar 

  47. Sauna ZE, Kimchi-Sarfaty C (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12(10):683–691. https://doi.org/10.1038/nrg3051

    Article  CAS  PubMed  Google Scholar 

  48. Shen LX, Basilion JP, Stanton VP Jr (1999) Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci USA 96(14):7871–7876

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Diekstra MHM, Klümpen HJ, Lolkema MPJK, Yu H, Kloth JSL, Gelderblom H, van Schaik RHN, Gurney H, Swen JJ, Huitema ADR, Steeghs N, Mathijssen RHJ (2014) Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662. Clin Pharmacol Ther 96(1):81–89. https://doi.org/10.1038/clpt.2014.47

    Article  CAS  PubMed  Google Scholar 

  50. Tulsyan S, Mittal RD, Mittal B (2016) The effect of ABCB1 polymorphisms on the outcome of breast cancer treatment. Pharmgenom Pers Med 9:47–58. https://doi.org/10.2147/PGPM.S86672

    Article  CAS  Google Scholar 

  51. Fung KL, Gottesman MM (2009) A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochem Biophys Acta 1794(5):860–871. https://doi.org/10.1016/j.bbapap.2009.02.014

    Article  CAS  PubMed  Google Scholar 

  52. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K (2002) Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther 71(4):297–303. https://doi.org/10.1067/mcp.2002.122055

    Article  CAS  PubMed  Google Scholar 

  53. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297(3):1137–1143

    CAS  PubMed  Google Scholar 

  54. Gurney H, Wong M, Balleine RL, Rivory LP, McLachlan AJ, Hoskins JM, Wilcken N, Clarke CL, Mann GJ, Collins M, Delforce SE, Lynch K, Schran H (2007) Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 82(1):33–40. https://doi.org/10.1038/sj.clpt.6100201

    Article  CAS  PubMed  Google Scholar 

  55. Wong M, Evans S, Rivory LP, Hoskins JM, Mann GJ, Farlow D, Clarke CL, Balleine RL, Gurney H (2005) Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 77(1):33–42. https://doi.org/10.1016/j.clpt.2004.09.002

    Article  CAS  PubMed  Google Scholar 

  56. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97(7):3473–3478. https://doi.org/10.1073/pnas.050585397

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Buda G, Ricci D, Huang CC, Favis R, Cohen N, Zhuang SH, Harousseau JL, Sonneveld P, Blade J, Orlowski RZ (2010) Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89(11):1133–1140. https://doi.org/10.1007/s00277-010-0992-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genom 15(10):693–704

    Article  CAS  Google Scholar 

  59. Muller PJ, Dally H, Klappenecker CN, Edler L, Jager B, Gerst M, Spiegelhalder B, Tuengerthal S, Fischer JR, Drings P, Bartsch H, Risch A (2009) Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients. Int J Cancer 124(7):1669–1674. https://doi.org/10.1002/ijc.23956

    Article  CAS  PubMed  Google Scholar 

  60. Mizuarai S, Aozasa N, Kotani H (2004) Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 109(2):238–246. https://doi.org/10.1002/ijc.11669

    Article  CAS  PubMed  Google Scholar 

  61. Imai Y, Nakane M, Kage K, Tsukahara S, Ishikawa E, Tsuruo T, Miki Y, Sugimoto Y (2002) C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141 K protein and low-level drug resistance. Mol Cancer Ther 1(8):611–616

    CAS  PubMed  Google Scholar 

  62. Tamura M, Kondo M, Horio M, Ando M, Saito H, Yamamoto M, Horio Y, Hasegawa Y (2012) Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci 74(1–2):133–140

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Eckford PD, Sharom FJ (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 109(7):2989–3011. https://doi.org/10.1021/cr9000226

    Article  CAS  PubMed  Google Scholar 

  64. Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochem Biophys Acta 1461(2):359–376

    Article  CAS  PubMed  Google Scholar 

  65. Mao Q, Qiu W, Weigl KE, Lander PA, Tabas LB, Shepard RL, Dantzig AH, Deeley RG, Cole SP (2002) GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [125I]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J Biol Chem 277(32):28690–28699. https://doi.org/10.1074/jbc.m202182200

    Article  CAS  PubMed  Google Scholar 

  66. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A, Sinnett D, Krajinovic M (2009) Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 114(7):1383–1386. https://doi.org/10.1182/blood-2008-11-191098

    Article  CAS  PubMed  Google Scholar 

  67. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100(10):3832–3834. https://doi.org/10.1182/blood.V100.10.3832

    Article  PubMed  Google Scholar 

  68. Lee YS, Kim BH, Kim BC, Shin A, Kim JS, Hong SH, Hwang JA, Lee JA, Nam S, Lee SH, Bhak J, Park JW (2015) SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma. Oncotarget 6(18):16449–16460. https://doi.org/10.18632/oncotarget.3758

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wan H, Zhu J, Chen F, Xiao F, Huang H, Han X, Zhong L, Zhong H, Xu L, Ni B, Zhong J (2014) SLC29A1 single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia: an in vitro study. J Exp Clin Cancer Res 33:90. https://doi.org/10.1186/s13046-014-0090-9

    Article  PubMed  PubMed Central  Google Scholar 

  70. Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM Jr, Schild SE, Zinner RG (2010) Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 28(4):614–619. https://doi.org/10.1200/jco.2009.23.6406

    Article  CAS  PubMed  Google Scholar 

  71. Jaruskova M, Curik N, Hercog R, Polivkova V, Motlova E, Benes V, Klamova H, Pecherkova P, Belohlavkova P, Vrbacky F, Machova Polakova K (2017) Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment. J Exp Clin Cancer Res 36(1):55. https://doi.org/10.1186/s13046-017-0523-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C (2010) The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 115(23):4671–4677. https://doi.org/10.1182/blood-2010-01-256958

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Minegaki T, Kuwahara A, Yamamori M, Nakamura T, Okuno T, Miki I, Omatsu H, Tamura T, Hirai M, Azuma T, Sakaeda T, Nishiguchi K (2014) Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int J Med Sci 11(4):321–326. https://doi.org/10.7150/ijms.7654

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Garcia-Casado Z, Guerrero-Zotano A, Llombart-Cussac A, Calatrava A, Fernandez-Serra A, Ruiz-Simon A, Gavila J, Climent MA, Almenar S, Cervera-Deval J, Campos J, Albaladejo CV, Llombart-Bosch A, Guillem V, Lopez-Guerrero JA (2010) A polymorphism at the 3′-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole. BMC Cancer 10:36. https://doi.org/10.1186/1471-2407-10-36

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Pastina I, Giovannetti E, Chioni A, Sissung TM, Crea F, Orlandini C, Price DK, Cianci C, Figg WD, Ricci S, Danesi R (2010) Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer 10:511. https://doi.org/10.1186/1471-2407-10-511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Paul S, Pant MC, Parmar D, Verma J (2011) Association and treatment response to capecitabine-based chemoradiotherapy with CYP2C9 polymorphism in head and neck cancer. Indian J Cancer 48(2):223–229. https://doi.org/10.4103/0019-509x.82899

    Article  CAS  PubMed  Google Scholar 

  77. Gor PP, Su HI, Gray RJ, Gimotty PA, Horn M, Aplenc R, Vaughan WP, Tallman MS, Rebbeck TR, DeMichele A (2010) Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 12(3):R26. https://doi.org/10.1186/bcr2570

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J, Sinnett D (2002) Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 8(3):802–810

    CAS  PubMed  Google Scholar 

  79. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH (2010) The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 103(6):765–771. https://doi.org/10.1038/sj.bjc.6605800

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Sukasem C, Sirachainan E, Chamnanphon M, Pechatanan K, Sirisinha T, Ativitavas T, Panvichian R, Ratanatharathorn V, Trachu N, Chantratita W (2012) Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev 13(9):4549–4553

    Article  PubMed  Google Scholar 

  81. Yang L, Zou S, Shu C, Song Y, Sun YK, Zhang W, Zhou A, Yuan X, Yang Y, Hu S (2017) CYP2A6 polymorphisms associate with outcomes of S-1 plus oxaliplatin chemotherapy in chinese gastric cancer patients. Genom Proteom Bioinform 15(4):255–262. https://doi.org/10.1016/j.gpb.2016.11.004

    Article  Google Scholar 

  82. Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, Dees EC (2013) CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel. Ann Oncol 24(6):1472–1478. https://doi.org/10.1093/annonc/mdt018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DJ, Rosenstein RB, Eagle CJ, Hawk ET, Bertagnolli MM (2009) Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology 136(7):2127–2136.e2121. https://doi.org/10.1053/j.gastro.2009.02.045

    Article  CAS  PubMed  Google Scholar 

  84. Yamada Y, Yamamoto N, Shimoyama T, Horiike A, Fujisaka Y, Takayama K, Sakamoto T, Nishioka Y, Yasuda S, Tamura T (2005) Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer Sci 96(10):721–728. https://doi.org/10.1111/j.1349-7006.2005.00109.x

    Article  CAS  PubMed  Google Scholar 

  85. Zandvliet AS, Huitema AD, Copalu W, Yamada Y, Tamura T, Beijnen JH, Schellens JH (2007) CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity. Clin Cancer Res 13(10):2970–2976. https://doi.org/10.1158/1078-0432.ccr-06-2978

    Article  CAS  PubMed  Google Scholar 

  86. Anthoney DA, Naik J, Macpherson IR, Crawford D, Hartley JM, Hartley JA, Saito T, Abe M, Jones K, Miwa M, Twelves C, Evans TR (2012) Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer 12:536. https://doi.org/10.1186/1471-2407-12-536

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Yazdi MF, Rafieian S, Gholi-Nataj M, Sheikhha MH, Nazari T, Neamatzadeh H (2015) CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev 16(15):6783–6787

    Article  PubMed  Google Scholar 

  88. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell’orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6):441–451. https://doi.org/10.1093/jnci/djs125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Abraham JE, Maranian MJ, Driver KE, Platte R, Kalmyrzaev B, Baynes C, Luccarini C, Shah M, Ingle S, Greenberg D, Earl HM, Dunning AM, Pharoah PD, Caldas C (2010) CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen. Breast Cancer Res 12(4):R64. https://doi.org/10.1186/bcr2629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Delord M, Rousselot P, Cayuela JM, Sigaux F, Guilhot J, Preudhomme C, Guilhot F, Loiseau P, Raffoux E, Geromin D, Genin E, Calvo F, Bruzzoni-Giovanelli H (2013) High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients. Oncotarget 4(10):1582–1591. https://doi.org/10.18632/oncotarget.1050

    Article  PubMed  PubMed Central  Google Scholar 

  91. Wang Y, Yin JY, Li XP, Chen J, Qian CY, Zheng Y, Fu YL, Chen ZY, Zhou HH, Liu ZQ (2014) The association of transporter genes polymorphisms and lung cancer chemotherapy response. PLoS One 9(3):e91967. https://doi.org/10.1371/journal.pone.0091967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Ruan Y, Jiang J, Guo L, Li Y, Huang H, Shen L, Luan M, Li M, Du H, Ma C, He L, Zhang X, Qin S (2016) Genetic association of curative and adverse reactions to tyrosine kinase inhibitors in chinese advanced non-small cell lung cancer patients. Sci Rep 6:23368. https://doi.org/10.1038/srep23368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Binder M, Zhang BY, Hillman DW, Kohli R, Kohli T, Lee A, Kohli M (2016) Common genetic variation in CYP17A1 and response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Int J Mol Sci 17:7. https://doi.org/10.3390/ijms17071097

    Article  CAS  Google Scholar 

  94. Ramnath N, Daignault-Newton S, Dy GK, Muindi JR, Adjei A, Elingrod VL, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Troeschel S, Johnson CS, Trump DL (2013) A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 71(5):1173–1182. https://doi.org/10.1007/s00280-013-2109-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Zeng H, Yu H, Lu L, Jain D, Kidd MS, Saif MW, Chanock SJ, Hartge P, Risch HA (2011) Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas 40(5):657–663. https://doi.org/10.1097/MPA.0b013e31821268d1

    Article  PubMed  PubMed Central  Google Scholar 

  96. Drenberg CD, Paugh SW, Pounds SB, Shi L, Orwick SJ, Li L, Hu S, Gibson AA, Ribeiro RC, Rubnitz JE, Evans WE, Sparreboom A, Baker SD (2016) Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther 99(6):651–660. https://doi.org/10.1002/cpt.315

    Article  CAS  PubMed  Google Scholar 

  97. Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA (2010) Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. J Thorac Oncol 5(9):1346–1353. https://doi.org/10.1097/JTO.0b013e3181ec18c4

    Article  PubMed  PubMed Central  Google Scholar 

  98. Green H, Soderkvist P, Rosenberg P, Horvath G, Peterson C (2008) ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel. J Pharm Sci 97(6):2045–2048. https://doi.org/10.1002/jps.21169

    Article  CAS  PubMed  Google Scholar 

  99. Hagleitner MM, Coenen MJ, Gelderblom H, Makkinje RR, Vos HI, de Bont ES, van der Graaf WT, Schreuder HW, Flucke U, van Leeuwen FN, Hoogerbrugge PM, Guchelaar HJ, te Loo DM (2015) A first step toward personalized medicine in osteosarcoma: pharmacogenetics as predictive marker of outcome after chemotherapy-based treatment. Clin Cancer Res 21(15):3436–3441. https://doi.org/10.1158/1078-0432.ccr-14-2638

    Article  CAS  PubMed  Google Scholar 

  100. Labib RM, Abdelrahim MEA, Elnadi E, Hesham RM, Yassin D (2016) CYP2B6rs2279343 is associated with improved survival of pediatric rhabdomyosarcoma treated with cyclophosphamide. PLoS One 11(7):e0158890. https://doi.org/10.1371/journal.pone.0158890

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, Tanigawara Y, Flockhart DA, Desta Z, Skaar TC, Aki F, Hirata K, Takatsuka Y, Okazaki M, Ohsumi S, Yamakawa T, Sasa M, Nakamura Y, Zembutsu H (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 28(8):1287–1293. https://doi.org/10.1200/jco.2009.25.7246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Kim IS, Kim HG, Kim DC, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Lee GW (2008) ABCG2 Q141 K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy. Cancer Sci 99(12):2496–2501. https://doi.org/10.1111/j.1349-7006.2008.00985.x

    Article  CAS  PubMed  Google Scholar 

  103. Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV (2009) Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 27(35):5972–5978. https://doi.org/10.1200/jco.2008.20.4156

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Kim SY, Baek JY, Oh JH, Park SC, Sohn DK, Kim MJ, Chang HJ, Kong SY, Kim DY (2017) A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysis. Radiat Oncol (London, England) 12(1):62. https://doi.org/10.1186/s13014-017-0800-5

    Article  CAS  Google Scholar 

  105. Melchardt T, Hufnagl C, Magnes T, Weiss L, Hutarew G, Neureiter D, Schlattau A, Moser G, Gaggl A, Trankenschuh W, Greil R, Egle A (2015) CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer. BMC Cancer 15:725. https://doi.org/10.1186/s12885-015-1776-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Mao JJ, Su HI, Feng R, Donelson ML, Aplenc R, Rebbeck TR, Stanczyk F, DeMichele A (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13(1):R8. https://doi.org/10.1186/bcr2813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Johnstone RW, Ruefli AA, Smyth MJ (2000) Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci 25(1):1–6

    Article  CAS  PubMed  Google Scholar 

  108. Kap EJ, Seibold P, Scherer D, Habermann N, Balavarca Y, Jansen L, Zucknick M, Becker N, Hoffmeister M, Ulrich A, Benner A, Ulrich CM, Burwinkel B, Brenner H, Chang-Claude J (2016) SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. Int J Cancer 138(12):2993–3001. https://doi.org/10.1002/ijc.30026

    Article  CAS  PubMed  Google Scholar 

  109. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramirez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ (2009) Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 27(16):2604–2614. https://doi.org/10.1200/jco.2008.20.6300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Singh O, Chan JY, Lin K, Heng CC, Chowbay B (2012) SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia. PLoS One 7(12):e51771. https://doi.org/10.1371/journal.pone.0051771

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Roberts JK, Birg AV, Lin T, Daryani VM, Panetta JC, Broniscer A, Robinson GW, Gajjar AJ, Stewart CF (2016) Population pharmacokinetics of oral topotecan in infants and very young children with brain tumors demonstrates a role of ABCG2 rs4148157 on the absorption rate constant. Drug Metab Dispos Biol Fate Chem 44(7):1116–1122. https://doi.org/10.1124/dmd.115.068676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, Foroni L, Kottaridis PD, Muller MC, Pirmohamed M, Clark RE (2013) The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121(4):628–637. https://doi.org/10.1182/blood-2012-01-405035

    Article  CAS  PubMed  Google Scholar 

  113. Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A, Stanulla M, Schrappe M, Langer T (2013) Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood 121(26):5145–5153. https://doi.org/10.1182/blood-2013-01-480335

    Article  CAS  PubMed  Google Scholar 

  114. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9(1):R7. https://doi.org/10.1186/bcr1640

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Kim KP, Jang G, Hong YS, Lim HS, Bae KS, Kim HS, Lee SS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW (2011) Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity. Br J Cancer 104(4):605–612. https://doi.org/10.1038/bjc.2011.17

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Kamataki T, Sasaki Y (2008) CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci 99(5):1049–1054. https://doi.org/10.1111/j.1349-7006.2008.00773.x

    Article  CAS  PubMed  Google Scholar 

  117. Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, Long B, Kammler R, Dell’Orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Harvey VJ, Neven P, Treilleux I, Rasmussen BB, Maibach R, Price KN, Coates AS, Goldhirsch A, Pagani O, Viale G, Rae JM, Regan MM (2015) CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Breast Cancer Res Treat 151(2):373–384. https://doi.org/10.1007/s10549-015-3378-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV (2016) Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin’s lymphoma. Eur J Cancer (Oxford, England: 1990) 55:56–64. https://doi.org/10.1016/j.ejca.2015.12.007

    Article  CAS  Google Scholar 

  119. Beelen K, Opdam M, Severson TM, Koornstra RH, Vincent AD, Hauptmann M, van Schaik RH, Berns EM, Vermorken JB, van Diest PJ, Linn SC (2013) CYP2C19 2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. Breast Cancer Res Treat 139(3):649–655. https://doi.org/10.1007/s10549-013-2568-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, Wingren S (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7(3):R284–R290. https://doi.org/10.1186/bcr993

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Li J, Czene K, Brauch H, Schroth W, Saladores P, Li Y, Humphreys K, Hall P (2013) Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment. Breast Cancer Res 15(5):R93. https://doi.org/10.1186/bcr3495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN (2013) CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 19(2):500–507. https://doi.org/10.1158/1078-0432.ccr-12-2153

    Article  CAS  PubMed  Google Scholar 

  123. Shukla P, Gupta D, Pant MC, Parmar D (2012) CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer. J Cancer Res Ther 8(1):40–45. https://doi.org/10.4103/0973-1482.95172

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The study was supported by the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University, and National Research Cancer of Thailand, and the Thailand Research Fund through the Royal Golden Jubilee PhD Program (Grant number PHD/0096/2560).

Author information

Authors and Affiliations

  1. Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), Pathumtani, 12121, Thailand

    Inthuorn Kulma, Kanyarat Boonprasert & Kesara Na-Bangchang

  2. Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Thammasat University (Rangsit Campus), Pathumtani, 12121, Thailand

    Inthuorn Kulma, Kanyarat Boonprasert & Kesara Na-Bangchang

  3. Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University (Rangsit Campus), Pathumtani, 12121, Thailand

    Kesara Na-Bangchang

Authors
  1. Inthuorn Kulma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kanyarat Boonprasert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kesara Na-Bangchang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kesara Na-Bangchang.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest in this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 456 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kulma, I., Boonprasert, K. & Na-Bangchang, K. Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review. Cancer Chemother Pharmacol 84, 959–975 (2019). https://doi.org/10.1007/s00280-019-03932-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03932-0

Keywords

Search

Navigation